The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have metastatic colorectal cancer. The purpose of this study to evaluate the experimental combination of 2 FDA approved drugs (cetuximab + palbociclib) in patients with metastatic colorectal cancer. The safety and effects of the experimental drug combination will be evaluated for this study.
Participation is approximately 4 months of drug treatment and possibly longer, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03446157
You will not receive any compensation/reimbursement for this study.